Short answer
Biohaven Ltd. (BHVN) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$131M
- +41.1% YoY
- EPS (diluted)
- −$0.88
- +59.4% YoY
Source: XBRL data from the Biohaven Ltd. (BHVN) Q1 2026 10-Q on SEC EDGAR. USD.
Biohaven Ltd. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue; no product-sales revenue expected in near term
- Key programs: BHV-1300 IgG reductions up to 87%; BHV-1400 Gd-IgA1 reductions up to 81%
- Opakalim worst development metric: 55% achieving ≥50% seizure reductions after six months at 75 mg
- Near-term milestones: pivotal BHV-1300 and BHV-1400 trials planned by mid-year 2026
- Opakalim RISE 3 topline results expected second half 2026; taldefgrobep Phase 2 results expected second half 2026
Risk Factors
- Newly issued 76,383 common shares valued at approximately $0.9 million under January 2026 Maskbegone Agreement
- Unregistered equity issuance relying on Securities Act Section 4(a)(2) exemption
- Exclusive tinnitus-development rights obtained for oxytocin and oxytocin derivatives
- No directors or officers adopted or terminated Rule 10b5-1 arrangements during quarter ended March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Biohaven Ltd. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.